Identification
- Generic Name
- Trabedersen
- DrugBank Accession Number
- DB05697
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Nucleic Acid Based Therapies
Oligonucleotides - Synonyms
- DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
- External IDs
- A-12009 FREE ACID
Pharmacology
- Indication
Investigated for use/treatment in brain cancer, colorectal cancer, melanoma, and pancreatic cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
AP 12009 is an antisense oligodeoxynucleotide that specifically inhibits TGF-beta2. TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation.
Target Actions Organism UTransforming growth factor beta-2 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Bupivacaine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Trabedersen sodium Q037WFO97F 871479-94-6 Not applicable - International/Other Brands
- Oncomun
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 98OYR854NY
- CAS number
- 925681-61-4
References
- General References
- Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P: Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):129-39. Epub 2005 Dec 27. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Terminated Treatment Anaplastic Astrocytoma (AA) / High Grade Glioma: Glioblastoma (GBM) 1 2 Completed Treatment Anaplastic Astrocytoma (AA) / High Grade Glioma: Glioblastoma (GBM) 1 2 Not Yet Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Withdrawn Treatment Metastatic Non-Small Cell Lung Cancer / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Lung Cancer AJCC v8 1 1 Completed Treatment Colorectal Neoplasms / Melanoma / Pancreatic Neoplasms 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Type iii transforming growth factor beta receptor binding
- Specific Function
- TGF-beta 2 has suppressive effects on interleukin-2 dependent T-cell growth.
- Gene Name
- TGFB2
- Uniprot ID
- P61812
- Uniprot Name
- Transforming growth factor beta-2
- Molecular Weight
- 47747.275 Da
References
- Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P: Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):129-39. Epub 2005 Dec 27. [Article]
Drug created at November 18, 2007 18:27 / Updated at May 05, 2021 20:39